A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice

In this work, we evaluated recombinant receptor binding domain (RBD)-based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus alum, AddaS03, AddaVax, or the combination of alum and U-Omp19: a novel Brucella spp. prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Coria, Lorena M., Saposnik, Lucas M., Pueblas Castro, Celeste, Castro, Eliana F., Bruno, Laura A., Stone, William B., Pérez, Paula S., Darriba, Maria Laura, Chemes, Lucia B., Alcain, Julieta, Mazzitelli, Ignacio, Varese, Augusto, Salvatori, Melina, Auguste, Albert J., Álvarez, Diego E., Pasquevich, Karina A., Cassataro, Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919065/
https://www.ncbi.nlm.nih.gov/pubmed/35296091
http://dx.doi.org/10.3389/fimmu.2022.844837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919065/
https://www.ncbi.nlm.nih.gov/pubmed/35296091
http://dx.doi.org/10.3389/fimmu.2022.844837

Ejemplares similares